Principal Financial Group Inc. Has $11.45 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Principal Financial Group Inc. lessened its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 9.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 575,953 shares of the biopharmaceutical company’s stock after selling 63,273 shares during the quarter. Principal Financial Group Inc.’s holdings in Catalyst Pharmaceuticals were worth $11,450,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in shares of Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 681 shares in the last quarter. nVerses Capital LLC acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at $50,000. CWM LLC boosted its stake in Catalyst Pharmaceuticals by 686.5% in the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 3,549 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in Catalyst Pharmaceuticals in the 2nd quarter valued at $70,000. Finally, SG Americas Securities LLC acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at $173,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on CPRX shares. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Truist Financial boosted their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Citigroup boosted their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $30.50.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Steve Miller sold 150,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the completion of the sale, the insider now owns 675,124 shares in the company, valued at $13,738,773.40. The trade was a 18.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director David S. Tierney sold 15,000 shares of the business’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the sale, the director now owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The trade was a 4.12 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $20.60 on Monday. The stock has a fifty day moving average price of $20.99 and a two-hundred day moving average price of $18.37. Catalyst Pharmaceuticals, Inc. has a 52-week low of $13.00 and a 52-week high of $24.27. The company has a market cap of $2.46 billion, a price-to-earnings ratio of 17.46, a PEG ratio of 3.17 and a beta of 0.75.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.